Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects

Neurobiology of Aging

Volumn 36, Issue 10, 2015, Pages 2791-2797

  Llado Saz, Sandra ^a   Atienza, Mercedes ^a   Cantero, Jose L ^a  

^a UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

Aging; Alzheimer's disease; Cognitive function; Cortical thickness; Homocysteine; Plasma amyloid beta

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITION; CORTICAL THINNING; EXECUTIVE FUNCTION; FEMALE; HUMAN; LANGUAGE ABILITY; LIPOPROTEIN BLOOD LEVEL; MALE; MEMORY; NERVOUS SYSTEM PARAMETERS; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TEMPORAL LOBE; TRIACYLGLYCEROL BLOOD LEVEL; ALZHEIMER DISEASE; BLOOD; BRAIN CORTEX; COGNITION DISORDERS; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBRAL CORTEX; COGNITION; COGNITION DISORDERS; FEMALE; HOMOCYSTEINE; HUMANS; MALE; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 84940943114     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.06.023     Document Type: Article

References (69)

1. Alarcon D., Fernandez C. Validación de la versión abreviada en español del Cuestionario de Funcionamiento de la Memoria (CFM) en una población mayor de 55 años. Anales de Psicologia 2008, 24:320-326.
2. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M.L., Volpe S., Ratto S., Dagna-Bricarelli F., Baldo C., Argusti A., Odetti P., Piccini A., Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004, 63:828-831.
3. Bernal-Rusiel J.L., Atienza M., Cantero J.L. Detection of focal changes in human cortical thickness: spherical wavelets versus Gaussian smoothing. Neuroimage 2008, 41:1278-1292.
4. Bernal-Rusiel J.L., Atienza M., Cantero J.L. Determining the optimal level of smoothing in cortical thickness analysis: a hierarchical approach based on sequential statistical thresholding. Neuroimage 2010, 52:158-171.
5. Bludau S., Eickhoff S.B., Mohlberg H., Caspers S., Laird A.R., Fox P.T., Schleicher A., Zilles K., Amunts K. Cytoarchitecture, probability maps and functions of the human frontal pole. Neuroimage 2014, 93(Pt 2):260-275.
6. Böhm P., Peña-Casanova J., Aguilar M., Hernandez G., Sol J.M., Blesa R. Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities. Int. Psychogeriatr. 1998, 10:261-270. NORMACODEN Group.
7. Bourgeat P., Chételat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O. Beta amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74:121-127. AIBL Research Group.
8. Cammarata S., Borghi R., Giliberto L., Pardini M., Pollero V., Novello C., Fornaro M., Vitali A., Bracco L., Caltagirone C., Bossù P., Odetti P., Tabaton M. Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. J. Alzheimers Dis. 2009, 18:267-271.
9. Christensen K., Doblhammer G., Rau R., Vaupel J.W. Ageing populations: the challenges ahead. Lancet 2009, 374:1196-1208.
10. Cosentino S.A., Stern Y., Sokolov E., Scarmeas N., Manly J.J., Tang M.X., Schupf N., Mayeux R.P. Plasma β-amyloid and cognitive decline. Arch. Neurol. 2010, 67:1485-1490.
11. Devanand D.P., Schupf N., Stern Y., Parsey R., Pelton G.H., Mehta P., Mayeux R. Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment. Neurology 2011, 77:125-131.
12. Dickerson B.C., Stoub T.R., Shah R.C., Sperling R.A., Killiany R.J., Albert M.S., Hyman B.T., Blacker D., Detoledo-Morrell L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011, 76:1395-1402.
13. Ding S.L., Van Hoesen G.W., Cassell M.D., Poremba A. Parcellation of human termporal polar cortex: a combined analysis of multiple cytoarchitectonic, chemoarchitectonic, and pathological markers. J. Comp. Neurol. 2009, 514:595-623.
14. Ertekin-Taner N., Younkin L.H., Yager D.M., Parfitt F., Baker M.C., Asthana S., Hutton M.L., Younkin S.G., Graff-Radford N.R. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 2008, 70:596-606.
15. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11050-11055.
16. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
17. Gläscher J., Tranel D., Paul L.K., Rudrauf D., Rorden C., Hornaday A., Grabowski T., Damasio H., Adolphs R. Lesion mapping of cognitive abilities linked to intelligence. Neuron 2009, 61:681-691.
18. Gonzalez-Escamilla G., Atienza M., Garcia-Solis D., Cantero J.L. Cerebral and blood correlates of reduced functional connectivity in mild cognitive impairment. Brain Struct. Funct. 2014, Epub ahead of print.
19. Hafkemeijer A., Altmann-Schneider I., Oleksik A.M., van de Wiel L., Middelkoop H.A., van Buchem M.A., van der Grond J., Rombouts S.A. Increased functional connectivity and brain atrophy in elderly with subjective memory complaints. Brain Connect. 2013, 3:353-362.
20. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31:357-367.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
22. Head E., Doran E., Nistor M., Hill M., Schmitt F.A., Haier R.J., Lott I.T. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J. Alzheimers Dis. 2011, 23:399-409.
23. Hof P.R., Mufson E.J., Morrison J.H. Human orbitofrontal cortex: cytoarchitecture and quantitative immunohistochemical parcellation. J. Comp. Neurol. 1995, 359:48-68.
24. Iacono D., Resnick S.M., O'Brien R., Zonderman A.B., An Y., Pletnikova O., Rudow G., Crain B., Troncoso J.C. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. J. Neuropathol. Exp. Neurol. 2014, 73:295-304.
25. Killiany R.J. Isn't amyloid more than just a marker for Alzheimer disease?. Neurology 2009, 73:1174-1175.
26. Kosaka T., Imagawa M., Seki K., Arai H., Sasaki H., Tsuji S., Asami-Odaka A., Fukushima T., Imai K., Iwatsubo T. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at Abeta42(43). Neurology 1997, 48:741-745.
27. Koyama A., Okereke O.I., Yang T., Blacker D., Selkoe D.J., Grodstein F. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch. Neurol. 2012, 69:824-831.
28. Kryscio R.J., Abner E.L., Cooper G.E., Fardo D.W., Jicha G.A., Nelson P.T., Smith C.D., Van Eldik L.J., Wan L., Schmitt F.A. Self-reported memory complaints: implications from a longitudinal cohort with autopsies. Neurology 2014, 83:1359-1365.
29. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., Van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
30. Lampert E.J., Roy Choudhury K., Hostage C.A., Petrella J.R., Doraiswamy P.M. Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives. PLoS One 2013, 8:e60747. Alzheimer's Disease Neuroimaging Initiative.
31. Lang P.O., Michel J.P., Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology 2009, 55:539-549.
32. Lobo A., Escoba V., Exquerra J., Sevar-Diaz A. Mini-Examen Cognoscitivo: Un test sencillo, práctico, para detectar alteraciones intelectuales en pacientes psiquiátricos. Actas Luso Esp Neurol. Psiquiatr Cienc Afines 1979, 3:189-202.
33. Lopez O.L. The growing burden of Alzheimer's disease. Am. J. Manag. Care 2011, 17(Suppl 13):S339-S345.
34. Lopez O.L., Kuller L.H., Mehta P.D., Becker J.T., Gach H.M., Sweet R.A., Chang Y.F., Tracy R., DeKosky S.T. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008, 70:1664-1671.
35. Lunney J.R., Lynn J., Foley D.J., Lipson S., Guralnik J.M. Patterns of functional decline at the end of life. JAMA 2003, 289:2387-2392.
36. McDonald B., Highley J.R., Walker M.A., Herron B.M., Cooper S.J., Esiri M.M., Crow T.J. Anomalous asymmetry of fusiform and parahipocampal gyrus gray matter in schizophrenia: a postmortem study. Am. J. Psychiatry 2000, 157:40-47.
37. Metti A.L., Cauley J.A., Ayonayon H.N., Harris T.B., Rosano C., Williamson J.D., Yaffe K. The demographic and medical correlates of plasma aβ40 and aβ42. Alzheimer Dis. Assoc. Disord. 2013, 27:244-249. Health, Aging and Body Composition Study.
38. Moon Y.S., Kang S.H., No H.J., Won M.H., Ki S.B., Lee S.K., Kim do H. The correlation of plasma Aβ42 levels, depressive symptoms, and cognitive function in the Korean elderly. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1603-1606.
39. National Institute of Aging., 2007. Why Population Aging Matters. National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
40. Norton S., Matthews F.E., Barnes D.E., Yaffe K., Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014, 13:788-794.
41. Okereke O.I., Xia W., Selkoe D.J., Grodstein F. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch. Neurol. 2009, 66:1247-1253.
42. Pacheco J., Goh J.O., Kraut M.A., Ferrucci L., Resnick S.M. Greater cortical thinning in normal older adults predicts later cognitive impairment. Neurobiol. Aging 2015, 36:903-908.
43. Pesaresi M., Lovati C., Bertora P., Mailland E., Galimberti D., Scarpini E., Quadri P., Forloni G., Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:904-905.
44. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
45. Rembach A., Watt A.D., Wilson W.J., Villemagne V.L., Burnham S.C., Ellis K.A., Maruff P., Ames D., Rowe C.C., Macaulay S.L., Bush A.I., Martins R.N., Masters C.L., Doecke J.D. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. J. Alzheimers Dis. 2014, 40:95-104. AIBL Research Group.
46. Roher A.E., Esh C.L., Kokjohn T.A., Castaño E.M., Van Vickle G.D., Kalback W.M., Patton R.L., Luehrs D.C., Daugs I.D., Kuo Y.M., Emmerling M.R., Soares H., Quinn J.F., Kaye J., Connor D.J., Silverberg N.B., Adler C.H., Seward J.D., Beach T.G., Sabbagh M.N. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009, 5:18-29.
47. Rosano C., Studenski S.A., Aizenstein H.J., Boudreau R.M., Longstreth W.T., Newman A.B. Slower gait, slower information processing and smaller prefrontal area in older adults. Age Ageing 2012, 41:58-64.
48. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
49. Rypma B., Berger J.S., Prabhakaran V., Bly B.M., Kimberg D.Y., Biswal B.B., D'Esposito M. Neural correlates of cognitive efficiency. Neuroimage 2006, 33:969-979.
50. Salat D.H., Buckner R.L., Snyder A.Z., Greve D.N., Desikan R.S., Busa E., Morris J.C., Dale A.M., Fischl B. Thinning of the cerebral cortex in aging. Cereb. Cortex 2004, 14:721-730.
51. Sanchez-Espinosa M.P., Atienza M., Cantero J.L. Sleep deficits in mild cognitive impairment are related to increased levels of plasma amyloid-β and cortical thinning. Neuroimage 2014, 98:395-404.
52. Saykin A.J., Wishart H.A., Rabin L.A., Santulli R.B., Flashman L.A., West J.D., McHugh T.L., Mamourian A.C. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006, 67:834-842.
53. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
54. Schupf N., Patel B., Silverman W., Zigman W.B., Zhong N., Tycko B., Mehta P.D., Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001, 301:199-203.
55. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113.
56. Seppälä T.T., Herukka S.K., Hänninen T., Tervo S., Hallikainen M., Soininen H., Pirttilä T. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J. Neurol. Neurosurg. Psychiatry 2010, 81:1123-1127.
57. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413. Alzheimer's Disease Neuroimaging Initiative.
58. Smith C.D., Chebrolu H., Wekstein D.R., Schmitt F.A., Jicha G.A., Cooper G., Markesbery W.R. Brain structural alterations before mild cognitive impairment. Neurology 2007, 68:1268-1273.
59. Sobów T., Flirski M., Kłoszewska I., Liberski P.P. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol. Exp. (Wars) 2005, 65:117-124.
60. Sotolongo-Grau O., Pesini P., Valero S., Lafuente A., Buendía M., Pérez-Grijalba V., José I.S., Ibarria M., Tejero M.A., Giménez J., Hernández I., Tárraga L., Ruiz A., Boada M., Sarasa M. Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume. Alzheimers Res. Ther. 2014, 6:56.
61. Sundelöf J., Giedraitis V., Irizarry M.C., Sundström J., Ingelsson E., Rönnemaa E., Arnlöv J., Gunnarsson M.D., Hyman B.T., Basun H., Ingelsson M., Lannfelt L., Kilander L. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch. Neurol. 2008, 65:256-263.
62. Toledo J.B., Shaw L.M., Trojanowski J.Q. Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker. Alzheimers Res. Ther. 2013, 5:8.
63. Tondelli M., Wilcock G.K., Nichelli P., De Jager C.A., Jenkinson M., Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol. Aging 2012, 33:825.e25-825.e36.
64. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006, 5:655-660.
65. Villeneuve S., Reed B.R., Madison C.M., Wirth M., Marchant N.L., Kriger S., Mack W.J., Sanossian N., DeCarli C., Chui H.C., Weiner M.W., Jagust W.J. Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. Neurology 2014, 83:40-47.
66. Walsh D.M., Selkoe D.J. Aβ oligomers-a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
67. Yaffe K., Weston A., Graff-Radford N.R., Satterfield S., Simonsick E.M., Younkin S.G., Younkin L.H., Kuller L., Ayonayon H.N., Ding J., Harris T.B. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011, 305:261-266.
68. Yesavage J.A., Brink T.L., Rose T.L., Lum O. Development and validation of a geriatric depression scale: a preliminary report. J. Psychiat. Res. 1983, 17:37-49.
69. Zahs K.R., Ashe K.H. β-amyloid oligomers in aging and Alzheimer's disease. Front. Aging Neurosci. 2013, 5:28.